Pilot Study on the Effects of IMOOVE in Parkinson's Disease Patients
Sponsored by IRCCS San Raffaele Roma
About this trial
Last updated 3 years ago
Study ID
IMOOVE-PD
Status
Completed
Type
Interventional
Phase
N/A
Placebo
No
Accepting
40 to 80 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 4 years ago
What is this trial about?
Parkinson's Disease (PD) is one of the most frequent causes of motor dysfunction in aging.
It is therefore important to use rehabilitative therapeutic approaches that may prevent the
development of motor complications when possible.
Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase
muscle tenfold.
The project is focused on quantifying the efficacy of IMOOVE® as a treatment method for
improving joint mobility, posture and autonomy in PD.
What are the participation requirements?
Inclusion Criteria
- Patients with Parkinson's Disease (diagnosed according to UK Brain Bank Criteria);
- Age: 40-80
- Medical treatment for Parkinson's Disease must be stable for at least two weeks prior to inclusion, and during the study. During the study, the dosage of anti-parkinsonian drug treatment should not change, if it is not deemed necessary by the investigator.-
Exclusion Criteria
- All the usual contraindications associated with physical medicine, rehabilitation and sport